Who Are the Core Customers in Tilray Brands Company's Target Market?

Tilray core customers center on recreational cannabis users in Canada and legalized international markets who buy branded flower and pre-rolls; this segment drove a large share of the cannabis revenue mix in fiscal 2025, with Canadian adult-use sales contributing to the company's cannabis gross revenue growth of ~$420 million in FY2025 (pro forma retail and wholesale channels).

Tilray target market includes medical cannabis patients in Germany, Poland, and Italy who purchase pharmaceutical-grade products; medical sales accounted for ~$110 million in FY2025 EU revenue. Wellness and CBD buyers (Manitoba Harvest) dominate North American hemp-based food aisles, contributing ~$175 million in FY2025 consumer-packaged goods revenue, serving CBD product consumer profiles and grocery buyers.

Tilray customer segments span direct consumers (recreational, medical, wellness) and B2B channels (dispensaries, distributors, wholesalers). The firm sells branded packaged goods in retail and wholesale; B2B distribution in Europe and North America represents a material portion of international medical and export sales.

Recreational cannabis users are strategically most important for scale and margin recovery in Canada, while the US craft-beverage segment became critical after Tilray acquired eight brands from Anheuser-Busch, making it the fifth largest US craft brewer and adding ~$240 million in FY2025 net revenue to the beverage pillar; together these two pillars now drive the largest share of consolidated revenue and investor interest.

The primary market is the United States beverage alcohol channel where Tilray core customers include craft-beer drinkers and retail buyers; beverage products now reach over 100,000 points of distribution, driving wide consumer exposure and strong retail velocity.

Canada remains the highest volume driver for recreational cannabis sales – Tilray customer demographics skew adult-use consumers – while Europe, led by Germany after 2024/2025 reforms, shows rising medical cannabis patient demand and prescription uptake.

Tilray Brands, Inc. is strongest where distribution and margin intersect: US craft beer channels and German medical pharmacies. Through CC Pharma, Tilray reaches approximately 13,000 pharmacies, supporting higher margin medical sales versus Canadian adult-use volume.

Demand is expanding fastest in Germany after regulatory reclassification lowered prescription barriers, and in the US craft beer sector where Tilray leverages beverage distribution growth; expect continued margin expansion in medical cannabis and beverage alcohol through 2025/2026.

Tilray expands reach by acquiring craft beer and beverage brands to access loyal drinkers and distribution networks, then cross – sells to recreational cannabis consumers and CBD and hemp product buyers. For 2025 Tilray core customers are broadened via retail and wholesale channels across Canada, the US, and Europe, with consolidated revenue approaching $900,000,000 and beverage alcohol contributing over 30% of the mix.

Retention relies on product innovation – sessionable beverages and higher – potency cannabis strains that match evolving tolerances – and distribution scale that keeps pricing competitive. Medical cannabis patients and millennial consumers show repeat demand through targeted SKUs and consistent supply to dispensaries and retailers.

Tilray drives loyalty via brand laddering across wellness, alcohol, and cannabis portfolios; B2B relationships with distributors and wholesalers deepen stickiness. Repeat purchases rise among CBD and hemp product buyers and recreational users as new SKUs and consistent pricing improve lifetime value.

The key lever is strategic acquisitions plus cross – platform brand laddering: buying craft beer and beverage brands provides immediate access to Tilray target market segments and distribution, positioning the firm to pivot to THC – infused beverages if US federal law changes. See Growth Outlook of Tilray Brands Company for context on 2025/2026 projections.